

## Lao PDR

### Support for Vaccine: PCV

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b>	Lao PDR						
<b>2. Vaccine grant number:</b>	13-LAO-08a-Y, 1315-LAO-12c-X, 16-LAO-12c-X, 17-LAO-12c-X, 1820-LAO-12d-X, 18-LAO-25a-Y						
<b>3. Date of Decision Letter:</b>	7-Jun-19						
<b>4. Date of the Partnership Framework Agreement:</b>	7-Jun-13						
<b>5. Programme title:</b>	New Vaccine Support (NVS), PCV, Routine						
<b>6. Vaccine type:</b>	PCV						
<b>7. Requested product presentation and formulation of vaccine:</b>	Pneumococcal (PCV13), 4 dose(s) per vial, LIQUID						
<b>8. Programme Duration:<sup>1</sup></b>	2013-2020						
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2013-2018	2019	2020	2021	2022	2023	Total <sup>2</sup>
Programme Budget (US\$)	8,319,908	661,500	676,000	-	-	-	9,657,408
<b>10. Vaccine introduction grant</b>							
	<b>Approval</b>						
	<b>Year</b>	<b>Grant Number</b>					<b>Amount</b>
	2013	13-LAO-08a-Y					150,000
	<b>Disbursement</b>						
	<b>Disbursement date</b>						<b>Amount (US\$)</b>
	08 July, 2013						150,000
<b>11. Product switch grant</b>							
	<b>Approval</b>						
	<b>Year</b>	<b>Grant Number</b>					<b>Amount</b>
	2018	18-LAO-25a-Y					45,000
	<b>Disbursement</b>						
	<b>Disbursement date</b>						<b>Amount (US\$)</b>
	06 July, 2018						45,000
<b>12. Indicative Annual Amounts:<sup>3</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						

<sup>1</sup>This is the entire duration of the Programme.

<sup>2</sup>This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the total amount approved by Gavi.

Type of supplies to be purchased with Gavi funds	2013-2018	2019	2020
Number of vaccine doses		181,600	-
Annual Amounts (US\$)	8,319,908	661,500	-

**13. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**14. Self-procurement:** Not applicable

**15. Co-financing obligations:**

According to the co-financing policy, the Country falls within the group: Accelerated transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020	2021	2022	2023
Number of vaccine doses	157,200	327,000	-	-	-
Number of AD syringes	145,800	324,900	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	1,625	3,600	-	-	-
Value of vaccine doses (US\$)	463,722	964,380	-	-	-
Total co-financing payments (US\$) (including freight)	476,500	991,000	-	-	-

**16. Operational support for catch-up campaigns:**

Not applicable

**17. Additional Reporting Requirements:**

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock, by end of March;</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2019</p> <p>15 May 2019</p>

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
---	------------------------------------

**18. Financial clarifications:**

Not applicable

**19. Other conditions:**

Not applicable

Signed by,

**On behalf of Gavi**



Hind Khatib-Othman

Managing Director, Country Programmes

7 June 2019